Vyne Therapeutics Inc (VYNE) Stock
VYNE is no longer traded. Vyne Therapeutics was delisted from the Nasdaq in July 2026.
Prices on this page are historical; the last trade was July 17, 2026 at $0.02.
Vyne Therapeutics stock price history
VYNE final trading statistics
- Final close
- $0.02
- Final trading day
- Jul 17, 2026
- Market cap at delisting
- $19.07M
- Shares outstanding
- 0.67M
- Final 52-week range
- $0.00 – $0.02
- Avg. volume (final 3 mo.)
- 562,845
- All-time high (split-adj.)
- $1.21 · Dec 2022
- All-time low (split-adj.)
- $0.00 · Oct 2018
- Return since IPO
- +6495.4%
- Beta
- 2.01
- Book value / share
- $36.93
- Price / book
- 0.00
Vyne Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $570.0K | -$26.5M | -$30.50 |
| FY2024 | $501.0K | -$39.8M | -$25.93 |
| FY2023 | $424.0K | -$28.5M | -$352.00 |
| FY2022 | $477.0K | -$23.2M | -$248.85 |
| FY2021 | $931.0K | -$73.3M | -$1152.54 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Vyne Therapeutics stock FAQ
What happened to Vyne Therapeutics stock?
Vyne Therapeutics stock was delisted from the Nasdaq. Its final close was $0.02 on July 17, 2026.
Is VYNE stock still trading?
No. VYNE was delisted from the Nasdaq in July 2026 and no longer trades on a U.S. exchange.
What was the last price of VYNE stock?
VYNE closed at $0.02 on its final trading day, July 17, 2026, for a market value of about $19.07M.
What were Vyne Therapeutics's revenue and earnings in its last full fiscal year?
Vyne Therapeutics reported revenue of $570.0K and net income of -$26.5M in fiscal 2025, its last full year as a public company.
When did Vyne Therapeutics go public?
Vyne Therapeutics Inc stock began trading on January 25, 2018.